Enumera Molecular

Ann Arbor, United States

Enumera Molecular is developing a scalable biomolecule assessment platform enabling lower-cost, rapid clinical liquid biopsy tests.

May 2022

Series A

Biotechnology Life Science Medical

Top Investors

Arboretum Ventures

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Enumera Molecular

Who are Enumera Molecular's investors?

Enumera Molecular's investors include Arboretum Ventures.

Where is Enumera Molecular headquartered?

Enumera Molecular is headquartered in Ann Arbor, United States.

What does Enumera Molecular do?

Enumera Molecular is developing a scalable biomolecule assessment platform enabling lower-cost, rapid clinical liquid biopsy tests.

What stage is Enumera Molecular at?

Enumera Molecular is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 5, 2022.

MLA

"Enumera Molecular — Funding & Investors." VCBacked, May 5, 2022, https://www.vcbacked.co/company/enumera-molecular. Accessed July 1, 2026.

APA

VCBacked. (2022). Enumera Molecular — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/enumera-molecular

Wikipedia (cite web)

{{cite web |title=Enumera Molecular — Funding & Investors |url=https://www.vcbacked.co/company/enumera-molecular |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 5, 2022.

Similar Companies in Biotechnology

View all

Rapport Therapeutics

Boston$250.0M

Renaissance BioScience

Vancouver

Neuroglee Therapeutics

Singapore

Living In Silico Inc.